(Q35564923)

8 August 2017

1 reference

title

Insulin-lowering agents in the management of polycystic ovary syndrome (English)

1 reference

PubMed ID

14570747

https://api.crossref.org/works/10.1210/ER.2002-0015

8 August 2017

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome (English)

1 reference

polycystic ovary syndrome

23 March 2024

main subject

1 reference

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1210/ER.2002-0015

23 March 2024

Vincenzo De Leo

1

0 references

Antonio La Marca

object named as

Antonio la Marca

2

0 references

Felice Petraglia

object named as

Felice Petraglia

3

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

PubMed ID

14570747

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14570747

23 March 2024

publication date

1 October 2003

1 reference

8 August 2017

1 reference

8 August 2017

24

1 reference

8 August 2017

633-667

1 reference

8 August 2017

5

1 reference

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

8 August 2017

https://api.crossref.org/works/10.1210/ER.2002-0015

1

1 reference

Cardiovascular consequences of polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

3

1 reference

The metabolic syndrome X.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

4

1 reference

Neuromodulation in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

6

1 reference

Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

7

1 reference

Gonadotropin Levels and Secretory Patterns in Patients with Typical and Atypical Polycystic Ovarian Disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

8

1 reference

Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

9

1 reference

Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

10

1 reference

A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

11

1 reference

Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

12

1 reference

An Attenuated Form of Congenital Virilizing Adrenal Hyperplasia*

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

13

1 reference

The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

14

1 reference

Differential control of luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone pulse frequency in man.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

15

1 reference

Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (GnRH) on gonadotropin secretion in GnRH-deficient men

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

16

1 reference

Neuroendocrine aspects of polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

17

1 reference

Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

18

1 reference

Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

19

1 reference

Evidence for the Importance of Peripheral Tissue Events in the Development of Hirsutism in Polycystic Ovary Syndrome*

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

20

1 reference

Combined Ovarian and Adrenal Vein Catheterization To Determine the Site(s) of Androgen Overproduction in Hirsute Women1

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

21

1 reference

Idiopathic Hirsutism — An Ovarian Abnormality

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

22

1 reference

Adrenal and ovarian contributions to the elevated free plasma androgen levels in hirsute women

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

23

1 reference

Ovarian hyperandrogenism with normal and abnormal histologic findings of the ovaries

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

24

1 reference

Ovarian responses to hCG stimulation: insulin resistance/hyperinsulinaemia vs. insulin deficiency

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

27

1 reference

Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

28

1 reference

CLINICAL AND BIOCHEMICAL FEATURES OF POLYCYSTIC OVARIAN DISEASE.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

32

1 reference

Do hyperandrogenic women with normal menses have polycystic ovary syndrome?

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

33

1 reference

Women with polycystic ovary syndrome gain regular menstrual cycles when ageing

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

34

1 reference

Polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

35

1 reference

Recurrent early miscarriage and polycystic ovaries

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

36

1 reference

An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

37

1 reference

Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

39

1 reference

Endocrinological and endometrial factors in recurrent miscarriage

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

40

1 reference

Polycystic ovaries and recurrent miscarriage--a reappraisal

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

41

1 reference

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

42

1 reference

Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

44

1 reference

Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

46

1 reference

Raised luteinising hormone and spontaneous miscarriage

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

47

1 reference

Recurrent miscarriage. II: Clinical associations, causes, and management

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

48

1 reference

Etiology of miscarriage in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

49

1 reference

Hypersecretion of luteinising hormone, infertility, and miscarriage

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

50

1 reference

Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

51

1 reference

Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

52

1 reference

Polycystic ovary disease. A risk factor for gestational diabetes?

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

53

1 reference

Obstetric outcome in women with polycystic ovarian syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

54

1 reference

High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

56

1 reference

Polycystic ovaries in women with gestational diabetes

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

57

1 reference

The prevalence of polycystic ovaries in women with a history of gestational diabetes.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

58

1 reference

Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

59

1 reference

Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

61

1 reference

Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

62

1 reference

High incidence of preeclamptic toxemia in patients with polycystic ovarian disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

63

1 reference

Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

64

1 reference

Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

65

1 reference

Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

66

1 reference

Polycystic ovary syndrome and cancer

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

67

1 reference

Cardiovascular risk in women with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

68

1 reference

Cardiovascular consequences of polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

69

1 reference

The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

70

1 reference

Metabolic aspects of polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

71

1 reference

Long-term health consequences of PCOS.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

72

1 reference

Insulin resistance and systemic hypertension

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

73

1 reference

Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

74

1 reference

Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

76

1 reference

Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

77

1 reference

Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

78

1 reference

Insulin resistance in essential hypertension

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

79

1 reference

Resistance to Insulin-Stimulated-Glucose Uptake in Patients with Hypertension*

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

80

1 reference

Insulin Resistance, Hyperinsulinemia, Dyslipidemia, Hypertension, and Accelerated Atherosclerosis

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

81

1 reference

Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

82

1 reference

Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

83

1 reference

Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

84

1 reference

Coronary heart disease risk factors in women with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

85

1 reference

Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

86

1 reference

Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

87

1 reference

The plasminogen activator system in women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

89

1 reference

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

90

1 reference

Clinical signs of androgen excess as risk factors for coronary artery disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

91

1 reference

Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

92

1 reference

Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

93

1 reference

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

94

1 reference

Mortality of women with polycystic ovary syndrome at long-term follow-up

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

95

1 reference

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

96

1 reference

Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

97

1 reference

Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

98

1 reference

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

99

1 reference

Banting lecture 1988. Role of insulin resistance in human disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

100

1 reference

Insulin resistance in polycystic ovarian syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

102

1 reference

Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

104

1 reference

Impact of family history of diabetes on the assessment of beta-cell function.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

105

1 reference

The prevalence of polycystic ovaries in women with type 2 diabetes mellitus.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

107

1 reference

Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

108

1 reference

Polycystic ovaries and the risk of breast cancer

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

113

1 reference

Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

114

1 reference

Insulin resistance: the clinical spectrum.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

115

1 reference

The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

117

1 reference

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

118

1 reference

Insulin resistance in nonobese patients with polycystic ovarian disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

119

1 reference

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

120

1 reference

Severe impairment of insulin action in adipocytes from amenorrheic subjects with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

121

1 reference

Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

123

1 reference

Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

126

1 reference

Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

127

1 reference

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

128

1 reference

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

129

1 reference

Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

131

1 reference

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

132

1 reference

Reproducibility of the oral glucose tolerance test and the rice-meal test in mild diabetics

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

133

1 reference

Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

134

1 reference

Efficacy of troglitazone measured by insulin resistance index

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

136

1 reference

Prediction models for insulin resistance in the polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

137

1 reference

The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

138

1 reference

Induction of ovulation in infertile women with hyperandrogenism and insulin resistance

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

139

1 reference

Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

141

1 reference

Clinical implications of hyperinsulinaemia in women

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

142

1 reference

Acanthosis nigricans in obese women with the polycystic ovary syndrome: disease spectrum not distinct entity

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

143

1 reference

Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

146

1 reference

Insulin receptor expression in follicular and stromal compartments of the human ovary over the course of follicular growth, regression and atresia.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

147

1 reference

Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

148

1 reference

Evidence for insulin resistance in nonobese patients with polycystic ovarian disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

149

1 reference

Tissue insulin sensitivity and body weight in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

150

1 reference

Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

152

1 reference

Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

153

1 reference

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

154

1 reference

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

155

1 reference

Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS).

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

156

1 reference

New insights into the role and mechanism of glycogen synthase activation by insulin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

157

1 reference

Altered autophosphorylation of the insulin receptor in the ovary of a woman with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

158

1 reference

Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

159

1 reference

Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

161

1 reference

Specific insulin binding sites in human ovary

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

163

1 reference

Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

165

1 reference

Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

166

1 reference

Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

167

1 reference

Somatomedin-C/insulin-like growth factor I as an enhancer of androgen biosynthesis by cultured rat ovarian cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

168

1 reference

Effects of inhibin-related peptides and oestradiol on androstenedione and progesterone secretion by bovine theca cells in vitro

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

169

1 reference

Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

170

1 reference

Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

171

1 reference

Plasma androgens and oestradiol during oral glucose tolerance test in patients with polycystic ovaries.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

172

1 reference

Androgen responses to acutely increased endogenous insulin levels in hyperandrogenic and normal cycling women

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

173

1 reference

Effect of Acute Physiological Elevations of Insulin on Circulating Androgen Levels in Nonobese Women*

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

174

1 reference

The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

175

1 reference

Hyperinsulinemia and hyperandrogenemia: in vivo androgen response to insulin infusion.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

176

1 reference

Androgen levels during sequential insulin euglycemic clamp studies in patients with polycystic ovary disease

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

177

1 reference

Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

178

1 reference

Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

179

1 reference

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

180

1 reference

Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

181

1 reference

Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

182

1 reference

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

183

1 reference

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

185

1 reference

The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

187

1 reference

23 March 2024

Insulin in the brain

https://api.crossref.org/works/10.1210/ER.2002-0015

188

1 reference

Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

189

1 reference

Role of brain insulin receptor in control of body weight and reproduction.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

190

1 reference

Insulin regulation of rat growth hormone gene transcription

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

191

1 reference

Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

192

1 reference

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

195

1 reference

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

196

1 reference

Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

197

1 reference

Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

198

1 reference

Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

199

1 reference

The relationship of sex hormones to hyperinsulinemia and hyperglycemia

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

200

1 reference

The relationship of insulin to sex hormone-binding globulin: role of adiposity

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

201

1 reference

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

202

1 reference

Interrelation between plasma sex hormone-binding globulin and plasma insulin in healthy adult women: the telecom study.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

203

1 reference

Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

205

1 reference

Insulin-like growth factor binding protein-1: recent findings and new directions.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

206

1 reference

Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

207

1 reference

The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

208

1 reference

Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

209

1 reference

The effects of insulin and insulin-like growth factors-I and -II on estradiol production by granulosa cells of polycystic ovaries.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

211

1 reference

Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

212

1 reference

Insulin-like growth factor-I regulates aromatase activity in human granulosa and granulosa luteal cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

213

1 reference

Regulation of gonadotropin-releasing hormone (GnRH) gene expression by insulin-like growth factor I in a cultured GnRH-expressing neuronal cell line

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

214

1 reference

Insulin-like growth factor-I effects on gonadotropin-releasing hormone biosynthesis in GT1-7 cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

215

1 reference

Effect of insulin-like growth factor I on gonadotropin release from the hypothalamus-pituitary axis in vitro.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

216

1 reference

Molecular biology of steroid hormone synthesis

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

219

1 reference

Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

220

1 reference

Permissive Effect of Insulin on the Adenosine 3′,5′-Monophosphate-Dependent Up-Regulation of Low Density Lipoprotein Receptors and the Stimulation of Steroid Release in Bovine Adrenal Cortical Cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

222

1 reference

Mechanisms of insulin inhibition of ACTH-stimulated steroid secretion by cultured bovine adrenocortical cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

223

1 reference

Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

224

1 reference

A possible interrelation between glucose-6-phosphate dehydrogenase and dehydroepiandrosterone in obesity

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

225

1 reference

Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

227

1 reference

Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

228

1 reference

Mechanisms of fatty acid-induced inhibition of glucose uptake

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

229

1 reference

Mechanism of free fatty acid-induced insulin resistance in humans

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

230

1 reference

The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

231

1 reference

The role of TNFalpha and TNF receptors in obesity and insulin resistance

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

233

1 reference

Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

234

1 reference

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

236

1 reference

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

237

1 reference

23 March 2024

Metformin--an update

https://api.crossref.org/works/10.1210/ER.2002-0015

238

1 reference

Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

239

1 reference

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

240

1 reference

Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

241

1 reference

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

243

1 reference

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

244

1 reference

Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

245

1 reference

Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

246

1 reference

Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

247

1 reference

Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

248

1 reference

Metformin and metoprolol CR treatment in non-obese men.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

251

1 reference

Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

254

1 reference

Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

255

1 reference

Cellular mechanism of action of metformin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

256

1 reference

Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

257

1 reference

Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

258

1 reference

23 March 2024

Biguanides and NIDDM

https://api.crossref.org/works/10.1210/ER.2002-0015

259

1 reference

Lactic acidosis in patients with diabetes treated with metformin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

260

1 reference

Metformin-induced acute hepatitis

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

261

1 reference

Effect of metformin on mouse embryo development

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

262

1 reference

Can metformin reduce insulin resistance in polycystic ovary syndrome?

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

264

1 reference

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

265

1 reference

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

266

1 reference

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

267

1 reference

Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

269

1 reference

The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

271

1 reference

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

272

1 reference

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

273

1 reference

Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

274

1 reference

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

275

1 reference

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

276

1 reference

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

277

1 reference

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

278

1 reference

Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

279

1 reference

Metformin directly inhibits androgen production in human thecal cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

280

1 reference

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

282

1 reference

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

283

1 reference

Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

284

1 reference

Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

285

1 reference

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

286

1 reference

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

289

1 reference

Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

290

1 reference

The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

291

1 reference

Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

292

1 reference

Identification of placental protein 14 as an immunosuppressive factor in human reproduction

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

294

1 reference

Vaginal color Doppler assessment of uterine artery impedance correlates with immunohistochemical markers of endometrial receptivity required for the implantation of an embryo.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

295

1 reference

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

296

1 reference

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

297

1 reference

Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

298

1 reference

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

299

1 reference

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

300

1 reference

Acute effects of troglitazone on in vivo insulin action in normal rats.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

301

1 reference

Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

302

1 reference

Adipogenesis and obesity: rounding out the big picture

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

304

1 reference

23 March 2024

Thiazolidinediones

https://api.crossref.org/works/10.1210/ER.2002-0015

305

1 reference

Thiazolidinediones: a new class of antidiabetic drugs

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

306

1 reference

Lessons from the glitazones: a story of drug development

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

307

1 reference

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

309

1 reference

Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

310

1 reference

Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

311

1 reference

Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

312

1 reference

High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

313

1 reference

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

316

1 reference

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

317

1 reference

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

318

1 reference

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

319

1 reference

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

320

1 reference

Interactions between glucose and FFA metabolism in man.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

322

1 reference

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

323

1 reference

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

324

1 reference

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

325

1 reference

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

326

1 reference

23 March 2024

Pioglitazone

https://api.crossref.org/works/10.1210/ER.2002-0015

327

1 reference

Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

328

1 reference

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

329

1 reference

Use of diphenylhydantoin and diazoxide to investigate insulin secretory mechanisms

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

330

1 reference

Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

331

1 reference

Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

332

1 reference

Diazoxide effects on biphasic insulin release: “adrenergic” suppression and enhancement in the perifused rat pancreas

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

333

1 reference

Leptin levels in women with polycystic ovary syndrome before and after treatment with diazoxide

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

334

1 reference

DIAZOXIDE THERAPY IN HYPERTENSION

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

335

1 reference

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

336

1 reference

Pharmacokinetic-pharmacodynamic relationships of Acarbose

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

337

1 reference

Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

338

1 reference

Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

339

1 reference

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

341

1 reference

Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

342

1 reference

Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

343

1 reference

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

344

1 reference

Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

345

1 reference

Acarbose reduces elevated testosterone serum concentrations in hyperinsulinaemic premenopausal women: a pilot study

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

346

1 reference

Photoaffinity labeling of the somatostatin receptor: identification of molecular subtypes

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

347

1 reference

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

348

1 reference

Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

349

1 reference

Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

350

1 reference

The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

352

1 reference

Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

353

1 reference

Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

356

1 reference

Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

357

1 reference

chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

358

1 reference

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

359

1 reference

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

360

1 reference

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

361

1 reference

Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

362

1 reference

Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

363

1 reference

Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

366

1 reference

The Effects on Plasma Lipoproteins of a Prudent Weight-Reducing Diet, with or without Exercise, in Overweight Men and Women

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

367

1 reference

Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

368

1 reference

Insulin resistance, secretion, and metabolism in users of oral contraceptives

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

369

1 reference

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

371

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

372

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

373

1 reference

Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

375

1 reference

Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

376

1 reference

Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome

23 March 2024

https://api.crossref.org/works/10.1210/ER.2002-0015

377

1 reference

23 March 2024

Identifiers

DOI

10.1210/ER.2002-0015

1 reference

8 August 2017

1 reference

PubMed ID

14570747